A Phase 1, Open Label, Dose Escalation Study of MGA271 (Fc-optimized Humanized Anti-B7-H3 Monoclonal Antibody) in Patients with Refractory B7- H3 Expressing Pediatric Cancers - Stand Up To Cancer

Blog

Posted October 11, 2019

A Phase 1, Open Label, Dose Escalation Study of MGA271 (Fc-optimized Humanized Anti-B7-H3 Monoclonal Antibody) in Patients with Refractory B7- H3 Expressing Pediatric Cancers

JOIN OUR COMMUNITY

Sign up to receive emails from Stand Up To Cancer.
   Please leave this field empty
Stand Up to Cancer

Thanks for signing up!
You will hear from us soon.

17028
Array
(
    [0] => 8
)
Array
(
    [0] => 8
)
Array
(
    [0] => 8
)